Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

P Rubinstein, Page C. Moore, Milan Bimali, Jeanette Y. Lee, Michelle A. Rudek, Amy Chadburn, Lee Ratner, David H. Henry, Ethel Cesarman, Camille E. DeMarco, Dominique Costagliola, Yassine Taoufik, Juan Carlos Ramos, Elad Sharon, Erin Reid, Richard F. Ambinder, Ronald T. Mitsuyasu, Nicolas Mounier, Caroline Besson, Ariela Noy, Stefan K. Barta, Ayad Hamdan, François Boué, Pierre Delobel, Lionel Galicier, Paul Coppo, Hervé Ghesquières